Scenesse® Phase 1 Trial Results Published. The multi-center, randomized trial ran for a six-month period and involved 55 vitiligo patients, all of whom received NB-UV-B phototherapy and half who also received Scenesse® (afamelanotide) in addition to the phototherapy.Scenesse® Phase 1 Trial Results Published Vitiligo is caused by the malfunction of the epidermal melanocytes. These melanocytes are responsible for growth of hair and the natural coloration of our skin. Melanin is secreted inorder to provide protection and color. This video explains the role of scenesse for vitiligo. The loss of melanin and melanocytes is not yet finalised. Clinuvel Pharmaceuticals, after many, many years, finally became a commercial operation with the introduction of Scenesse as the first treatment for EPP. While EPP is a very profitable first Afamelanotide's inclusion on the 648/96 list has been formally announced by Italian legislators, allowing the drug to be prescribed to patients with immediate effect. [update:] Clinuvel have also announced that afamelanotide will be marketed under the brand name of Scenesse (pronounced "sen-esse"). From today onwards, Clinuvel will adopt of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. SCENESSE® IN VITILIGO For personal use only. This free 1 hour webinar is a summary of the special Vitiligo issue in the April 2017 Dermatologic Clinics (available on Amazon here). In this webinar I discuss different presentations of vitiligo, the best treatments for it, genetics, role of diet and supplements, depigmenting therapies, and much INSPIRE VITILIGO PROGRAM UPDATE Vitiligo is a disease which causes white or off-white depigmented skin lesions to appear on different parts of the body due to a loss of melanin (pigment) production. This disorder may spread over time and cause patients significant psychological and emotional distress. Scenesse is a subcutaneous implant administered every two months by a healthcare professional proficient in the subcutaneous implantation procedure. Patients should maintain sun protection measures during treatment with Scenesse to prevent phototoxic reactions related to erythropoietic protoporphyria. Scenesse is used to help prevent or reduce these symptoms so that these patients can lead more normal lives. Because the number of patients with EPP is low, the disease is considered 'rare', and Scenesse was designated an 'orphan medicine' (a medicine used in rare diseases) on 8 May 2008. Scenesse contains the active substance Afamelanotide (melanotan I, brand name Scenesse) is a synthetic peptide and analogue of ?-melanocyte stimulating hormone used to prevent skin damage from the sun in people with erythropoietic protoporphyria in Europe since January 2015, and the United States since October 2019. As a medicine sold under the brand name "Scenesse", it is administered in subcutaneous implant form; the implant